The upcoming multi-center, multinational Phase 1 study will evaluate safety, tolerability, pharmacokinetics, and early signs of efficacy
Routine regulatory filing confirms completion of demat and share transfer compliances for March quarter
The India FMCG business showed a sequential recovery and is expected to post high-single digit growth
The acquisition adds VYKAT XR (diazoxide choline), the first FDA-approved therapy for hyperphagia in Prader-Willi syndrome (PWS), a rare genetic disorder, to Neurocrine’s portfolio
Approval for 5 mg and 10 mg strengths, bioequivalent to Farxiga®, strengthens Lupin’s anti-diabetic portfolio in US market
The acquisition aims to bolster Merck’s hematology portfolio with Terns’ lead oncology candidate, TERN-701
As part of the deal, Red Nucleus also gains indirect ownership of the company’s Indian arm
The company has highlighted setbacks in Phase II studies while outlining fresh regulatory and late-stage development plans for Fibromun and Nidlegy
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
The investigational new drug application with FDA was actually for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate aimed at solid tumors
Subscribe To Our Newsletter & Stay Updated
